Tracing breast cancer HER2 with a special scan
Part of Cancer, Skin clinical trials.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor's HER2 status must already be known from a previous biopsy.
- Your blood counts, liver, and kidney function must be within certain limits.
- You cannot be currently receiving chemotherapy or targeted therapy.
- If you could become pregnant, you must have a negative pregnancy test and use birth control for 30 days after the study.
- You cannot have another type of cancer or a serious active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that may help doctors see breast cancer more clearly. The test uses a radioactive tracer that attaches to a protein on cancer cells, which could help plan your treatment.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This trial uses a special PET scan to see if your breast cancer has low levels of a protein called HER2. This could help doctors choose the right treatment for you.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
Hear when a new Primary Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.